Lupin hit with more regulatory challenges

By Maggie Lynch

- Last updated on GMT

(Image: Getty/	Shidlovski)
(Image: Getty/ Shidlovski)

Related tags Fda facility Manufacturing Inspection Lupin Pharmaceuticals India contamination

Lupin’s facility was given six observations after the FDA closed its inspection earlier this month.

No details of the observations made at the Indore, India, site have been released. The Indian drugmaker stated that it is working towards addressing the observations.

Lupin has faced a number of regulatory issues over the past few months.

Most recently, the company recalled 42 lots of its antibiotic​, Ceftriaxone, after contaminant was found in the vials.

In December 2018, Lupin received 22 observations​ across three of its facilities at its Mandideep campus, after an inspection by the US Food and Drug Administration (FDA) in late November.

At the time, Lupin stated that the observations were “largely procedural in nature,” ​after the FDA identified gaps in the facility’s aseptic processing areas of its active pharmaceutical ingredient (API) manufacturing block.

However, the FDA did give Lupin the all clear for the company’s manufacturing process for its ‘sartan’, despite discovering one “procedural deficiency.”

Valsartan, losartan, and irbesartan are all APIs that have been making headlines after a carcinogen​, N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) had been found to contaminate certain medicines.

During the FDA’s inspection for NDMA and NDEA contaminants, it did observe a procedural deficiency at the company’s site in Tarpur, India, which encompasses 14 manufacturing plants and five solvent recovery blocks. 

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more